The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound

INTRODUCTION: Drug resistance against dolutegravir (DTG) or the nucleosides with which it has been co-administered has never been observed in patients receiving this drug in first-line therapy. In contrast, a R263K mutation that confers low-level resistance (3–4 fold) to DTG has been selected by DTG...

Descripción completa

Detalles Bibliográficos
Autores principales: Wainberg, Mark, Anstett, Kaitlin, Mesplede, Thibault, Quashie, Peter, Han, Yingshan, Oliveira, Maureen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Oral Presentation – Abstract O332
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224880/
https://www.ncbi.nlm.nih.gov/pubmed/25394027
http://dx.doi.org/10.7448/IAS.17.4.19518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224880/
https://www.ncbi.nlm.nih.gov/pubmed/25394027
http://dx.doi.org/10.7448/IAS.17.4.19518

Ejemplares similares